The global uveitis treatment market size was valued at USD 493.91 million in 2018 and is expected to witness lucrative CAGR of 5.8% over the forecast period. Rising incidence of uveitis is the major factor driving the growth. According to The College of Optometrists, the incidence of anterior uveitis is 12 per 100,000 people annually. On the basis of a study on medical records from California communities, uveitis leads to 30,000 new cases of blindness each year contributing to nearly 10% of all the blind cases.
Growing R&D activities in the field of ophthalmology has also lead to high growth of the market. Increasing number of clinical trials for eye inflammation treatment are being conducted globally. A large number of novel phase III clinical trials are under development for refractory posterior or intermediate uveitis. For instance, a phase III trial is in process for determining the effectiveness of mycophenolate mofetil and methotrexate as a standard corticosteroid treatment for noninfectious posterior, intermediate, and panuveitis cases. Rising R&D activities for biological drugs is another significant factor that has led to effective treatment of eye inflammation disorder. These factors are expected to drive the demand for such drugs, thereby, driving market growth.
With growing cases of infectious diseases, the prevalence of uveitis with infectious etiologies is also rising. It is most common in the developing countries. According to the Indian Journal of Inflammation Research, in India, around 50% of the uveitis cases are caused by infections. Developing countries are also highly susceptible to eye inflammation due to infectious etiologies.
On the basis of treatment type, corticosteroids held the largest market share in 2018, due to the fact that it is considered as the primary treatment for patients with noninfectious uveitis. Corticosteroid drugs are very useful for minimizing inflammation. Various types of corticosteroid eye drops available in the market are approved by the Food and Drug Administration (FDA). Ophthalmologists commonly recommend eye drops, oral medications, or injections of corticosteroids.
Corticosteroid implants are also increasingly gaining traction for people with chronic eye inflammation disorders. For instance, Retisert, manufactured by Bausch+Lomb is the first FDA approved surgical corticosteroid implant for treating noninfectious posterior uveitis in U.S.
Monoclonal antibodies is anticipated to showcase lucrative CAGR over the forecast period owing to the rapid development of biologic drugs. Some of the commonly used biologic drugs include Infliximab, Interferon, Alefacept, Etanercept, Daclizumab, and Efalizumab among others.
Anterior uveitis led the market space in 2018 due to high prevalence of the condition among the adults as well as the young population. In addition, increasing research in this field highlights that this type of disease grows with age. There is high risk for people with untreated anterior uveitis leading to loss of vision as well as development of cataract, glaucoma, or retinal edema.
Posterior uveitis is expected to witness lucrative growth during the study period owing to the availability of various drugs. For instance, Trivaris, by Allergan is a corticosteroid used for its prevention. However, poor penetration of topical corticosteroids to the posterior portion of the eye is expected to restrain the uveitis treatment market.
Intermediate uveitis is anticipated to showcase significant growth over the forecast period because it facilitates prevention of permanent structural damage to vital ocular tissue. In addition, rising prevalence of various infectious diseases like tuberculosis, leprosy, Lyme’s disease, syphilis, toxocariasis, and whipple’s disease is expected to lead to rising cases of intermediate uveitis.
On the basis of cause segment, noninfectious uveitis generated significant market revenue in 2018 owing to the wide availability of various treatment options. Corticosteroids, antibiotics, immunosuppressants, and biologic drugs are some of the treatment types commonly used for noninfectious uveitis. Moreover, it is mostly prevalent in the developed regions of the world.
Infectious uveitis also held considerable market share in 2018 owing to the rising prevalence of infectious diseases in the developing countries. It can affect various portions of the eye, from anterior to posterior. According to the American Academy of Ophthalmology, syphilis, sarcoidosis, and tuberculosis are found in most of the patients diagnosed with this condition.
On the basis of distribution channel, hospital pharmacies led the market in 2018 due to the availability of a wide array of options for the management of eye inflammation in the hospitals. Moreover, hospitals provide treatment and care to a large number of patients, thereby making hospital pharmacies a leading segment.
Online pharmacies is expected to witness significant CAGR over the forecast period due to the growing convenience in choosing from online websites that provide a wide range of drugs along with extensive product information. In addition, rising popularity of the e-commerce distribution channels offering prescribed medicines at discounted prices is another factor driving the growth.
In 2018, North America led the market owing to the rising prevalence of noninfectious uveitis in U.S. In addition, advanced healthcare facilities and favorable reimbursement policies are attributed to propel the regional growth. Large number of drugs are commercially available in U.S., which is further boosting the demand from the country.
Europe generated significant revenue in 2018 owing to the growing R&D initiatives as well as rising healthcare expenditure in the region. Increasing number of aging population is also a significant factor driving the regional growth. Asia Pacific, on the other hand, is anticipated to exhibit lucrative CAGR during the forecast period, mainly due to the rising incidence of infectious diseases and lack of hygiene in the developing region. Growing awareness regarding the various treatment alternatives has also led to high regional growth.
Major market players include Allergan, Inc.; Bausch & Lomb Incorporated; Santen Pharmaceutical Co., Ltd; AbbVie Inc.; Novartis AG; Eyegate Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Eyepoint pharmaceuticals Inc.; and Alimera Sciences, Inc.
Key manufacturers are increasingly adopting strategic initiatives such as new product development, mergers and acquisitions, and regional expansions. For instance, in 2018, EyePoint Pharmaceuticals, Inc. received U.S. FDA approval for YUTIQ, an implant used for treating non-infectious uveitis that affects the posterior segment of the eye.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Japan, India, China, South Korea, Singapore, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global uveitis treatment market report on the basis of treatment type, disease type, cause, distribution channel, and region:
Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)
Disease Type Outlook (Revenue, USD Million, 2015 - 2026)
Cause Outlook (Revenue, USD Million, 2015 - 2026)
Distribution Channel Outlook (Revenue, USD Million, 2015 - 2026)
Regional Outlook (Revenue, USD Million, 2015 - 2026)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."